
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
The U.S. Food and Drug Administration (FDA) is warning the public about "adverse events" associated with some "permanent" makeup treatments.